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Nowadays, there are plenty of anticancer drugs on the market, and yet there is still an issue 
in its clinical usage. This is not caused by the absence of anticancer activity, more likely 
caused by the low bioavailability and high toxicity. Therefore, it motivates researchers to 
continue the research on effective and safe novel anticancer drug. Synthesis and activity test 
towards the  novel drug are time consuming and costly. In the past, it is even impossible to 
predict bioavailability, anticancer activity, and toxicity. However, along with the development 
of new software to predict bioavailability, activity, and toxicity, such issues are becoming 
more manageable. This approach will  ensure benefit in terms of efficiency. It can minimize 
the amount of trial and error during the process of novel drug candidate selection. Following 
the use of this software, if the prospective drug compound is predicted to have anti-cancer 
activity with low bioavailability and high toxicity, further synthesis and activity test in 
laboratory are no longer needed.  
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Introduction 
The field of anticancer therapeutics is at a 
critical point in its development.  
http://www.who.int/news-room/fact-sheets/detail/cancer 
1 February 2018 
 
Key facts 
1. Cancer is the second leading cause of death globally, and was responsible  
    for 8.8 million deaths in 2015.  
2. Globally, nearly 1 in 6 deaths is due to cancer. 
3. Approximately 70% of deaths from cancer occur in low- and middle- 
    income countries. 
4. Around one third of deaths from cancer are due to the 5 leading  
    behavioral and dietary risks: high body mass index, low fruit and vegetable   
    intake, lack of physical activity, tobacco use, and alcohol use. 
5. Tobacco use is the most important risk factor for cancer and is responsible  
    for approximately 22% of cancer deaths (2). 
6. Cancer causing infections, such as hepatitis and human papilloma virus (HPV), are  
     responsible for up to 25% of cancer cases in low- and middle-income countries   
     (3). 
7. Late-stage presentation and inaccessible diagnosis and treatment are common. In  
    2017, only 26% of low-income countries reported having pathology services  
    generally available in the public sector. More than 90% of high-income countries  
    reported treatment services are available compared to less than 30% of low- 
    income countries. 
8. The economic impact of cancer is significant and is increasing. The total annual  
    economic cost of cancer in 2010 was estimated at approximately US$ 1.16 trillion  
    (4). 
9. Only 1 in 5 low- and middle-income countries have the necessary data to drive  
     cancer policy (5). 
Cancer is a leading cause of death worldwide, accounting for 8.8 million 
deaths in 2015.  
 
The most common causes of cancer death are cancers of: 
 
•Lung (1.69 million deaths) 
•Liver (788 000 deaths) 
•Colorectal (774 000 deaths) 
•Stomach (754 000 deaths) 




Anticancer drug discovery  
has continued to be 
a very interesting field of 
research, but synthesis and 
activity test towards the  novel 
drug are time consuming and 
costly. 
Drug discovery steps: 
1.Drug Design, 
2.Synthesis and 
3.Evaluation of New Anticancer 
Drugs 
Many drugs still fail in cancer patient therapy even 
after advanced clinical trials and safety testing, 
why?  
 
The answer is usually a result of an unfavorable 
absorption, distribution, metabolism, and 
excretion/toxicity (ADME/T) profile.  
 
In the past, it was difficult to almost 
impossible to predict these characteristics 
for a specific compound. Drug discovery in 
the new millennium is armed with not 
only new and efficient techniques for 
producing, purifying and screening new 
entities, but with computing power that 
was unimaginable a decade ago. Hence, 
with data compiled from other 
commercial agents, we can a priori predict 
ADME/T properties of lead molecules in 
silico  
CADD (Computer Aided Drug Design) 
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Drug discovery steps become: 
1.Computer Aided Drug Design, 
2.Synthesis and 
3.Evaluation of NewAnticancer 
Drugs 
IN SILICO ADME-TOX STUDY 
Ex. CDI-lab, pkCSM, The Pentium IV work station and Pallas 6.1.1 software were 
used to calculate and to predict the ADMET properties of the molecules.  
Chem draw ultra software was used to draw the structure of the compounds to be 
analyzed and was saved as MDL file. The sketched molecules were undergo 
calculation of the following properties viz drug likeliness, metabolite, toxicity, etc. 
 
IN SILICO ACTIVITY TEST  BY MOLECULAR DOCKING only involve electronic and 
steric properties. 
Ex. MVD 5.0, Autodoc, MOE, Maestro, etc. 
It needs to check lipophylic property. The predicted drug likeliness of the 
compounds follow the Lipinski “Rule of Five” that all four parameter values for a 
compound are less than five for log P and H-bond donors and multiples of five for 
H-bond acceptors and molecular weight showed that the compounds might have 








The 3D pharmacophore search is an important, robust and a facile 
approach to rapidly identify lead compounds against a desired 
target. Traditionally, a pharmacophore is defined as the specific 3D 
arrangement of functional groups within a molecular framework 
that are necessary to bind to a macromolecule and/or an enzyme 
active site. The designation of a pharmacophore is the first essential 
step towards understanding the interaction between a receptor and 
a ligand. Once a pharmacophore is established, the medicinal 
chemist has a host of 3D database search tools to retrieve novel 
compounds that fit the pharmacophore model. The search 
algorithms have evolved over the years to effectively identify and 
optimize leads, focus combinatorial libraries and assist in virtual 
high-throughput screening. Thus, this technology has been clearly 
established as one of the successful computational tools in modern 
drug design  
HIGH-THROUGHPUT DOCKING 
Docking is simply active or a designated site of a protein and 
referred to the ability to position a ligand in the calculate 
specific binding affinities. Ligand-protein docking has evolved so 
remarkably throughout the past decade that docking single or 
multiple small molecules to a receptor site is now routinely used 
to identify ligands. Optimal docking procedures need to be fast, 
generate reliable ligand geometries, rank the ligand 
conformation correctly (scoring), and thereby, estimate the 
binding energy. A number of studies have shown that docking 
algorithms are capable of finding ligands and binding 
conformations at a receptor site close to experimentally 
determined structures (see below). These algorithms are equally 
applicable to the identification of multiple proteins to which a 
small molecule can bind. The application of this approach may 
facilitate the prediction of either unknown and secondary 
therapeutic target proteins or side effects and toxicity of 
particular drugs  
Target Protein Kinases for Cancer & 
Small molecule inhibitors 
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The large number of validated targets and new drugs have 
been developed. Modern anticancer drug research has 
become increasingly focused on targeted drug therapy, and 
many of the validated targets are transduction-related 
macromolecules. In the 1980s, protein kinases were first 
shown to have an important role in oncogenesis and tumor 
progression, and since then they have received increasing 
attention as targets for anticancer drugs. Several 
kinase inhibitors are now approved for the treatment of 
cancer, and many more are advancing through clinical trials.  
 
Protein kinases (PTKs) are enzymes that regulate the 
biological activity of proteins by phosphorylation of specific 
amino acids with ATP as the source of phosphate, thereby 
inducing a conformational change from 
an inactive to an active form of the protein 
 
Most PTKs are related to oncogenes, and approximately 16 of them 
are considered as possible therapeutic targets. Based on their 
localization and structure, these enzymes are classified as receptor- or 
non-receptor PTKs. Receptor protein kinases (RPTKs) have dual 
roles: as receptors and as enzymes. 
They have a hydrophobic domain that transverses the cell membrane, 
an extracellular ligand-binding 
domain that recognizes an external messenger (growth hormones or 
growth factors), and a cytoplasmatic kinase domain that becomes 
activated upon binding of the external messenger, triggering a 
signaling cascade that ultimately controls the transcription of specific 
genes related to cellular proliferation and differentiation. 
 
Non-receptor PTKs are activated by upstream signaling molecules 
such as G protein-coupled receptors, immune system receptors, or 
RPTKs. They have no transmembrane or extracellular domains and 
are not covalently bound to a membrane receptor, nor anchored to 
the phospholipid membrane via a lipid modification.  
 
Ligand binding to a RPTK induces its dimerization or oligomerization, 
leading to interactions between adjacent cytoplasmic domains with 
accompanying activation of the kinase moiety. Activation of a non-
receptor kinase is similarly induced in response to the appropriate 
extracellular signal, but dimerization may or may not be necessary for 
activation. The activated kinase then initiates a cascade of 
phosphorylation reactions resulting in the activation of other 
proteins, as well as the production of secondary messengers that 
transmit the signal to the nucleus. 
All protein kinases have a region in their active site that recognizes 
ATP, which is the phosphorylating 
agent in all cases, as well as another region for their substrates. Most 
clinically used inhibitors interact with these ATP recognition sites that, 
despite having a common substrate, are relatively different for 
different kinases, making possible some selectivity in the inhibition. 
Very often, structurally close compounds bind to the ATP site in 
different topologies and are able to recognize different kinases.  
For this reason, chemical similarity between kinase inhibitors often 
fails to correlate with target specificity. 
Binding to an adjacent allosteric site or to an inactive form of the 
kinase has also been exploited.  
 
 
In Targeting Protein Kinases for Cancer 
Therapy, the drugs that inhibit them are 
called small molecule inhibitors. 
Compounds (usually a small organic 
molecule) demonstrate a desired 
biological activity on a validated molecular 
target.  
Some of Selected Kinase Inhibitors in the 





Trials design to evaluate targeted agents  
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LEAD OPTIMIZATION 
Starting with the prospective lead compound to structural 
modification in order to develope structure-activity 
relationship (SAR) and quantitative SAR (QSAR) one can 
gain tremendous information. These approaches have 
been modified remarkably and the researcher now has a 
plethora of resources under his/her disposal before the 
actual synthesis begins.  

On February 13, 2015, lenvatinib (Lenvima; Eisai),  
An oral, multireceptor tyrosine kinase inhibitor, was approved 
by the US Food and Drug Administration (FDA) 
to treat patients with locally recurrent or metastatic, 
progressive, radioactive iodine–refractory differentiated 
thyroid cancer.  
 
FDA approves lenvatinib for unresectable hepatocellular 
carcinoma [news release]. Silver Spring, MD; August 16, 2018:  
FDA website. http://www.pharmacytimes.com/link/206. 
  
Accessed August 16, 2018. 
 

Structural modification  
of 1-benzyl-3-benzoylurea lead compound 
by inserting  22 lipophilic and electronic groups 
into benzoyl group in order to increase activity 
 
The same pharmacophore compare to 
Lenvatinib is the reason to do molecular 
docking all test compound as VEGFR-2 




Lipinski “Rule of five”result 


Prediction % absorbtion using pkCSM  

 
No. Compound Rerank Score(kcal/mol) 
1 1-benzyl-3-benzoylurea -90.3715 
2 1-benzyl-3-(2-chloroo)-benzoylurea -91.2155 
3 1-benzyl-3-(3- chloro)-benzoylurea -87.166 
4 1-benzyl-3-(4-chloro)-benzoylurea -85.6658 
5 1-benzyl-3-(2,4-dichloro)-benzoylurea -83.9519 
6 1-benzyl-3-(3,4-dichloro)-benzoylurea -81.8889 
7 1-benzyl-3-(4-chloromethyl)-benzoylurea -82.1469 
8 1-benzyl-3-(3-chloromethyl)-benzoylurea -86.0169 
RMSD = 0,646062 
Prediction in-silico activity using Molegro Virtual Docker 5.0 
 
9 1-benzyl-3-(2- chloromethyl)-benzoylurea -86.5096 
10 1-benzyl-3-(4-methyl)-benzoylurea -81.9729 
11 1-benzyl-3-(4-ethyl)-benzoylurea -82.5089 
12 1-benzyl-3-(3-ethyl)-benzoylurea -83.5294 
13  1-benzyl-3-(2-ethyl)-benzoylurea -91.5842 
14 1-benzyl-3-(4-propyl)- benzoylurea -88.1971 
15 1-benzyl-3-(4-t-butyl)- benzoylurea -80.853 
16 1-benzyl-3-(4-fluoro)-benzoylurea -89.4971 
17 1-benzyl-3-(2-trifluoromethyl)-benzoylurea -86.5934 
18 1-benzyl-3-(3-trifluoromethyl)-benzoylurea -87.4362 
19 1-benzyl-3-(4-trifluoromethyl)-benzoylurea -82.601 
20 1-benzyl-3-(4-bromo)-benzoylurea -82.5543 
21 1-benzyl-3-(4- bromomethyl)- benzoylurea -81.4373 
22 1-benzyl-3-(4- nitro)-benzoylurea -88.6502 
23 1-benzyl-3-(4- methoxy)-benzoylurea -84.0985 
 Hydroxyurea -44.5302 
 5-fluorouracil -52.6336 
 Lenvatinib -124.545 
ProTox-Predicition of Rodent Oral Toxicity  
 
No. Compound Toxicity  Parameter LD-50 (mg/kg) 
1 1-benzyl-3-benzoylurea 1950 
2 1-benzyl-3-(2-chloroo)-benzoylurea 3000 
3 1-benzyl-3-(3- chloro)-benzoylurea 2000 
4 1-benzyl-3-(4-chloro)-benzoylurea 2000 
5 1-benzyl-3-(2,4-dichloro)-benzoylurea 2000 
6 1-benzyl-3-(3,4-dichloro)-benzoylurea 2000 
7 1-benzyl-3-(4-chloromethyl)-benzoylurea 1950 
8 1-benzyl-3-(3-chloromethyl)-benzoylurea 3000 
9 1-benzyl-3-(2- chloromethyl)-benzoylurea 3000 
10 1-benzyl-3-(4-methyl)-benzoylurea 818 
11 1-benzyl-3-(4-ethyl)-benzoylurea 2000 
12 1-benzyl-3-(3-ethyl)-benzoylurea 2000 
13  1-benzyl-3-(2-ethyl)-benzoylurea 2000 
14 1-benzyl-3-(4-propyl)- benzoylurea 2000 
15 1-benzyl-3-(4-t-butyl)- benzoylurea 2000 
16 1-benzyl-3-(4-fluoro)-benzoylurea 2000 
17 1-benzyl-3-(2-trifluoromethyl)-benzoylurea 3000 
18 1-benzyl-3-(3-trifluoromethyl)-benzoylurea 2000 
19 1-benzyl-3-(4-trifluoromethyl)-benzoylurea 818 
 
20 1-benzyl-3-(4-bromo)-benzoylurea 2000 
21 1-benzyl-3-(4- bromomethyl)- benzoylurea 1950 
22 1-benzyl-3-(4- nitro)-benzoylurea 2850 
23 1-benzyl-3-(4- methoxy)-benzoylurea 2000 
 Hydroxyurea 5760 
 5-fluorouracil 115 
 Lenvatinib 3000 
COMPOUND 
 
Lipinski “Rule of 
five”result 
 
%  Abs. 
prediction result 
In silico activity 
prediction result 
(RS  , kkcal/mol) 
Toxicity  
prediction result 
(LD50,  mg/kg) 
All Meet the 
requirement 
82.368- 92.733 -81,4173 –  
-91,5842 
818-3000 
Lenvatinib Meet the 
requirement 
 
84.799 -124,545 3000 
General result 
What are your recommendation??? 
Some of test compounds are recommended 
to further synthesize and advance activity test 
Computer-Aided Drug 
Design (CADD) or Structure-
Based Drug Design (SBDD) 
has made a time minimizing 
to the field of novel 
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